ATHIRA PHARMA, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • March 28th, 2022 • Athira Pharma, Inc. • Biological products, (no disgnostic substances) • Washington
This Change in Control and Severance Agreement (the “Agreement”) is made by and between Athira Pharma, Inc., a Delaware corporation (the “Company”), and Kevin Church (“Executive”), effective as of January 31, 2022 (the “Effective Date”).
November 17, 2021 Hans Moebius, M.D., Ph. D. Via Email Re: Amendment to Employment Agreement Dear Hans:Employment Agreement • March 28th, 2022 • Athira Pharma, Inc. • Biological products, (no disgnostic substances)
Reference is made to that certain employment offer letter dated September 13, 2020 (the “Offer Letter”) between you and Athira Pharma, Inc. (the “Company”). As discussed, the Compensation Committee of the Board of Directors of the Company has approved amendments to the terms of your employment as set forth below. Except as otherwise amended hereby, the terms of the Offer Letter remain in full force and effect. Capitalized terms in this letter have the same definitions as the Offer Letter. The amendments are effective retroactive to October 1, 2021.
